Clinical trial
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in…
NCT00087646 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00087646 |
|---|---|
| Title | REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy |
| Official title | A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Ribavirin, peginterferon alfa-2a [Pegasys] |
| Enrollment | 948 |
| Start date | Sep 1, 2003 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jul 14, 2004 |
| Last update posted | Jan 14, 2016 |
| Countries | Belgium, Brazil, Canada, France, Germany, Greece, Italy, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye) and 2 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: